title: Local injection of infliximab in symptomatic isolated mucosal lesions: a novel scenario for endoscopic therapy?
authors.forename: V
authors.initials: V
authors.lastname: Lorenzo-Zúñiga
authors.forename: J
authors.initials: J
authors.lastname: Boix
authors.forename: M
authors.initials: M
authors.lastname: Mañosa
authors.forename: C
authors.initials: C
authors.lastname: Lezcano
authors.forename: E
authors.initials: E
authors.lastname: Cabré
authors.forename: V
authors.initials: V
authors.lastname: Moreno de Vega
authors.forename: E
authors.initials: E
authors.lastname: Domènech
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D003092:Colitis / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D003424:Crohn Disease / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D005260:Female; D005765:Gastrointestinal Agents / Q000008:administration & dosage*; D006801:Humans; D007079:Ileitis / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D000069285:Infliximab; D007275:Injections, Intravenous; D008297:Male; D011379:Prognosis; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D055815:Young Adult
chemical_list: D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab